Singapore legislation
Regulation 2
Regulation 2
Definitions
In this Order —“Class 2 CTGT product” has the meaning given by regulation 2(1) of the Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021;“customs office” means any place prescribed as such under the Customs (Offices and Stations) Regulations (Rg 7);“customs station” means any place prescribed as such under the Customs (Offices and Stations) Regulations;“customs territory”, “dutiable goods”, “Government warehouse”, “intoxicating liquor”, “licensed warehouse”, “proper officer of customs” and “senior officer of customs” have the meanings given by section 3(1) of the Customs Act 1960;“Director‑General” means the Director‑General of Customs appointed under the Customs Act 1960 and includes any person mentioned in section 4(3) of that Act;“export inspection station” means —
Pasir Panjang Export Inspection Station situated at 19 Harbour Drive, Singapore 117402; (b)Brani Export Inspection Station situated at 71 Brani Terminal Avenue, Singapore 098326; or (c)Tuas Export Inspection Station situated at Cargo Inspection Centre, 73 Tuas South Boulevard, Singapore 636744;“medicinal product” has the meaning given by the Medicines Act 1975;“protocol”, in relation to any regulated clinical trial, means a document that describes the objectives, design, methodology, statistical considerations and organisation of the trial;“regulated clinical trial” means any clinical trial —
for which a clinical trial certificate is issued under regulation 8 of the Medicines (Clinical Trials) Regulations 2016; or
that is authorised by the Health Sciences Authority, or notified to the Health Sciences Authority and the notification of which is accepted by the Health Sciences Authority, under regulation 8 or 9 of the Health Products (Clinical Trials) Regulations 2016;“therapeutic product” means a health product categorised as a therapeutic product in the First Schedule to the Health Products Act 2007.
Definition
“Class 2 CTGT product” has the meaning given by regulation 2(1) of the Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021;
Definition
“customs office” means any place prescribed as such under the Customs (Offices and Stations) Regulations (Rg 7);
Definition
“customs station” means any place prescribed as such under the Customs (Offices and Stations) Regulations;
Definition
“customs territory”, “dutiable goods”, “Government warehouse”, “intoxicating liquor”, “licensed warehouse”, “proper officer of customs” and “senior officer of customs” have the meanings given by section 3(1) of the Customs Act 1960;
Definition
“Director‑General” means the Director‑General of Customs appointed under the Customs Act 1960 and includes any person mentioned in section 4(3) of that Act;
Definition
“export inspection station” means —
Pasir Panjang Export Inspection Station situated at 19 Harbour Drive, Singapore 117402; (b)Brani Export Inspection Station situated at 71 Brani Terminal Avenue, Singapore 098326; or (c)Tuas Export Inspection Station situated at Cargo Inspection Centre, 73 Tuas South Boulevard, Singapore 636744;
Definition
“medicinal product” has the meaning given by the Medicines Act 1975;
Definition
“protocol”, in relation to any regulated clinical trial, means a document that describes the objectives, design, methodology, statistical considerations and organisation of the trial;
Definition
“regulated clinical trial” means any clinical trial —
for which a clinical trial certificate is issued under regulation 8 of the Medicines (Clinical Trials) Regulations 2016; or
that is authorised by the Health Sciences Authority, or notified to the Health Sciences Authority and the notification of which is accepted by the Health Sciences Authority, under regulation 8 or 9 of the Health Products (Clinical Trials) Regulations 2016;
Definition
“therapeutic product” means a health product categorised as a therapeutic product in the First Schedule to the Health Products Act 2007.